Literature DB >> 15321838

Familial hypercholesterolemia and coronary heart disease: a HuGE association review.

Melissa A Austin1, Carolyn M Hutter, Ron L Zimmern, Steve E Humphries.   

Abstract

Familial hypercholesterolemia (FH) is an autosomal disorder characterized by increased levels of total cholesterol and low density lipoprotein cholesterol. The FH clinical phenotype has been shown to be associated with increased coronary heart disease and premature death. Mutations in the low density lipoprotein receptor gene (LDLR) can result in the FH phenotype, and there is evidence that receptor-negative mutations result in a more severe phenotype than do receptor-defective mutations. Mutations in the apolipoprotein B-100 gene (APOB) can result in a phenotype that is clinically indistinguishable from familial hypercholesterolemia, and mutations in this gene have also been shown to be associated with coronary heart disease. Preliminary research indicates that the FH phenotype is influenced by other genetic and environmental factors; however, it is not clear if these are synergistic interactions or simply additive effects.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15321838     DOI: 10.1093/aje/kwh237

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  74 in total

1.  Long-Term Risk of Atherosclerotic Cardiovascular Disease in US Adults With the Familial Hypercholesterolemia Phenotype.

Authors:  Amanda M Perak; Hongyan Ning; Sarah D de Ferranti; Holly C Gooding; John T Wilkins; Donald M Lloyd-Jones
Journal:  Circulation       Date:  2016-07-05       Impact factor: 29.690

2.  Seniors' perceptions of prescription drug advertisements: a pilot study of the potential impact on informed decision making.

Authors:  Jerry L Grenard; Visith Uy; José A Pagán; Dominick L Frosch
Journal:  Patient Educ Couns       Date:  2010-11-01

Review 3.  Genetic lipoprotein disorders and coronary atherosclerosis.

Authors:  Mahmoud Alawadhi; George Thanassoulis; Michel Marcil; Jacques Genest
Journal:  Curr Atheroscler Rep       Date:  2005-05       Impact factor: 5.113

4.  MicroRNA-management of lipoprotein homeostasis.

Authors:  Xinghui Sun; Mark W Feinberg
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

5.  Lipoprotein-apheresis: Austrian consensus on indication and performance of treatment.

Authors:  Kurt Derfler; Sabine Steiner; Helmut Sinzinger
Journal:  Wien Klin Wochenschr       Date:  2015-07-23       Impact factor: 1.704

6.  A model of care for familial hypercholesterolaemia: key role for clinical biochemistry.

Authors:  Gerald F Watts; David R Sullivan; Frank M van Bockxmeer; Nicola Poplawski; Ian Hamilton-Craig; Peter M Clifton; Richard C O'Brien; Peter M George; John R Burnett
Journal:  Clin Biochem Rev       Date:  2012-02

7.  Predicting non-adherence in patients with familial hypercholesterolemia.

Authors:  J M H Galema-Boers; M J Lenzen; R T van Domburg; J Roeters van Lennep; G G van Bruchem-van de Scheur; E J Sijbrands; J G Langendonk
Journal:  Eur J Clin Pharmacol       Date:  2014-01-22       Impact factor: 2.953

Review 8.  Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options.

Authors:  Adam N Berman; Ron Blankstein
Journal:  Curr Cardiol Rep       Date:  2019-08-05       Impact factor: 2.931

Review 9.  Novel Therapies for Familial Hypercholesterolemia.

Authors:  Justin Parizo; Ashish Sarraju; Joshua W Knowles
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-11

Review 10.  Optimal management of familial hypercholesterolemia: treatment and management strategies.

Authors:  Mohammad Hassan Nemati; Behrooz Astaneh
Journal:  Vasc Health Risk Manag       Date:  2010-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.